Promoter holding
64.27%
GP
Grindlays Pharmaceuticals Pvt Ltd - Due diligence report
A 360° intelligence report on Grindlays Pharma: trust score, financial health, credit view, compliance, directors, growth and distress signa…
Full Due-Diligence Report + Documents
- Unlock all financial figures & 5-year trends
- Full trust, health & credit-risk scores
- Director details, charges & MCA documents
₹700
₹449
Save ₹251
excl. GST
Or from ₹279/report with credits
View credit packages
Company Credits – Starter
- One credit unlocks this full due-diligence report
- Use across any company’s report, anytime
- Credits valid for 12 months
Choose your own credit amount
View credit packages
Grindlays Pharma — 360° Intelligence Report
Generated from MCA filings & public records95/100
Trust Score
Low Risk
Grindlays Pharma is assessed as Low Risk with a Trust Score of 95/100. Grindlays Pharma is an active private limited indian non-government company incorporated in 1985, operating in the Pharma sector. The company has shown revenue growth across its recent filed years. It was profitable in its latest filed year. Based on MCA filings and public records, it currently shows a low compliance risk and low financial risk profile.
Report generated on 12 Aug 2026 from the latest processed filings. Grindlays Pharmaceuticals Pvt Ltd snapshot & full profile →
Automated indicators derived from public MCA / GST / EPFO records - not a credit rating, not investment, legal or financial advice. Spotted an inaccuracy? Report an error.
02
Score Card
Higher is safer · rule-based & explainableTrust ScoreLow Risk
95/100
Overall counterparty trust - the headline number of this report.
Compliance ScoreLow Risk
100/100
Statutory standing - status, filings, auditor, MSME and litigation.
Financial Health ScoreLow Risk
90/100
Profitability, leverage and liquidity from filed statements.
Credit Risk ScoreModerate
60/100
Debt capacity, gearing and security cover for lenders.
Director Stability ScoreLow Risk
95/100
Board strength, DIN status, churn and network.
Growth ScoreLow Risk
95/100
Revenue, profit, asset and hiring momentum.
Distress ScoreLow Risk
90/100
Early-warning signals - higher means fewer warnings.
03
Financial Intelligence Dashboard
Standalone · 5 filed year(s)Unlock the full 5-year financial dashboard with charts and year-wise figures.
Get full accessScores and observations on this page are already computed from the real filings - only the underlying figures are locked.
04
Credit & Compliance Intelligence
Why the scores are what they are
Credit Risk Score: 60/100 Moderate
- Open charges exceed net worth - secured lenders rank ahead.
- Working-capital cover adequate.
- Profitable - internal accruals available.
Charges position: 1 open (5.86 cr) · 7 satisfied (9.60 cr).
Banking relationships (from registered charges)
| Lender | Charges | Amount |
|---|---|---|
| Bank Of India | 4 | 48.0 cr |
| Deutsche Bank Ag | 1 | 48.0 cr |
| State Bank Of India | 3 | 48.0 cr |
Compliance Score: 100/100 Low Risk
- Company status is Active as per MCA.
- Annual filings current (balance sheet Mar 2025).
- 1 active GST registration(s).
05
Director Intelligence
Stability score: 95/100| Name | DIN / PAN | Designation | Appointed | Tenure | DIN status |
|---|---|---|---|---|---|
| ARTI RAMKRISHNA KOLWANKAR | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| RAMKRISHNA HARISHET KOLWANKAR | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| SANTOSH RAMKRISHNA KOLWANKAR | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| DHANASHRI GIRISH GUDI | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
- 4 directors on the board.
- No disqualified or deactivated DINs.
- Stable board - no exits in 3 years.
- Average tenure above 5 years.
Director & KMP remuneration (FY 2017)
| Name | Designation | Total remuneration |
|---|---|---|
| A K Sharma | Managing Director | 2.4 cr |
| R Mehta | Whole-time Director | 1.6 cr |
| S Iyer | CFO | 95.0 L |
Remuneration is disclosed in the latest annual return. Unlock full report
06
Ownership & Group Intelligence
As per FY 2022 annual returnPublic / other holding
35.73%
Equity shares
12,45,67,890
Equity paid-up
124.5 cr
Promoters on record
4
Ultimate holding entity
-
Subsidiaries
-
Group entities
-
Capital events
3 allotment(s) · 0 transfer(s)
Promoters hold a dominant controlling stake - exact percentages are part of the full report.
Key managerial personnel: RAMKRISHNA HARISHET KOLWANKAR (Managing Director)
Full shareholding pattern, group structure & capital events →
07
Risk Intelligence Center
Growth 95 · Distress 90
Growth signals & trust indicators
Steady revenue growth: +38% over 4 year(s).
Latest year revenue grew 1.42.
Profit expanded 2.1x year-on-year.
Asset base grew 24% - capacity expansion.
Net margin improved to 0.86.
EPFO headcount growing - hiring signal.
Operating for 40+ years.
Active EPFO - real payroll on record.
Active GST registration(s).
Distress signals & risk flags
1 open charge(s) registered - assets are encumbered.
08
Stakeholder Verdicts
Vendor · Banker · InvestorVendor due diligence95/100
Favourable indicators
Suitability as a supplier / customer counterparty.
- Statutory record is clean.
- No distress signals on file.
- Financial filings available for verification.
Banker assessment79/100
Favourable lending indicators
Indicative lending comfort for banks, NBFCs and trade credit.
- Debt capacity assessed from filed statements.
- 1 open charge(s) of 5.86 cr already registered.
- Compliance record supports lending.
Investor view93/100
Positive growth indicators
Growth quality and scalability through an investor lens.
- 6 growth signal(s) detected.
- Margin and return trends computable from filings.
- Management team looks stable.
09
MCA Filings & Events Timeline
Latest 15 events30 Sep 2025
Last AGM held
Annual general meeting
31 Mar 2025
Latest balance sheet
Filed with ROC
14 Dec 2020
Charge satisfied
Bank Of India
19 Nov 2020
Charge satisfied
Deutsche Bank Ag
30 Sep 2014
Director ceased
SANTOSH RAMKRISHNA KOLWANKAR
31 Jul 2013
Charge created
Deutsche Bank Ag - 3.55 cr
28 Mar 2012
Securities allotted
225000 Equity Shares Without Differential Rights - 22.50 Lakh raised
01 Aug 2011
Securities allotted
149300 Equity Shares Without Differential Rights - 14.93 Lakh raised
14 Jun 2011
Securities allotted
125700 Equity Shares Without Differential Rights - 12.57 Lakh raised
16 Nov 2009
Director appointed
SANTOSH RAMKRISHNA KOLWANKAR (Director)
22 Jun 2009
Charge satisfied
State Bank Of India
03 Jun 2009
Charge satisfied
State Bank Of India
18 Mar 2009
Charge created
Bank Of India - 12.00 Lakh
27 Sep 2008
Charge created
Bank Of India - 3.50 cr
Charge created
Bank Of India - 5.86 cr
10
Key Observations
Auto-generated from the data aboveRevenue grew 61% over the last 4 financial year(s).
Net profit margin moved from 38% to 1.42.
Debt-to-equity stands at 2.1x - leverage worth monitoring.
Net worth is positive.
Compliance record is strong - status, filings and flags are clean.
4 active director(s) / partner(s); board looks stable and experienced.
1 active GST registration(s) indicate ongoing business operations.
EPFO-registered employer - verifiable payroll history exists.
Promoters hold a dominant controlling stake as per the FY 2022 annual return.
Director / KMP remuneration is disclosed in the latest annual return - exact figures available in the full report.
Capital has been raised through 3 security allotment(s) - amounts available in the full report.
| Company | CIN | Location |
|---|---|---|
| Gargi Chemicals Private Limited | U24110MH1977PTC019480 | Mumbai, Maharashtra, India |
| Alcedo Pharmachem Private Limited | U24239TG2016PTC111056 | Serilingampally, Telangana, India |
| Gurjar Chemicals Private Limited | U02424MP2006PTC018485 | Indore, Madhya Pradesh, India |
| Hi Tech Biosciences India | U24232PN2007PTC130033 | Pune, Maharashtra, India |
| Staywell Formulation Private Limited | U24233DL2007PTC170595 | New Delhi, Delhi, India |
| Damani Dyestuff Limited | U24299GJ1977PLC003018 | Distt Bharuch, Gujarat, India |
| Mexican Agro Chemical Limited | U24219MP2002PLC014932 | Indore, Madhya Pradesh, India |
| Corpora Consultants Private Limited | U74900HR2011PTC042068 | Gurgaon, Haryana, India |
12
Who Uses This Report
CA · CS · Banker · Investor · VendorChartered Accountants (CA)
Verify Grindlays Pharma before audits and certifications: compliance score 100/100, filing history, auditor history and charge records in one place - instead of pulling each MCA form separately.
Company Secretaries (CS)
Track statutory health of Grindlays Pharma: ACTIVE compliance status, annual-return recency, director DIN status, board churn and the events timeline - the inputs for secretarial audits and due-diligence certificates.
Bankers & NBFCs
Current banker verdict: Favourable lending indicators. Credit risk score 60/100, existing charge position and lender relationships - a first-pass credit memo before formal appraisal.
Investors & Analysts
Investor view: Positive growth indicators. Growth score 95/100, margin trends, ownership structure and peer set for Grindlays Pharma - screening before a deeper diligence.
Vendors & Procurement Teams
Vendor verdict: Favourable indicators. Trust score 95/100, distress signals and MSME payment-delay disclosures - know whether Grindlays Pharma pays its suppliers before you extend credit terms.
Lawyers & Compliance Teams
Litigation footprint (no cases on record), regulatory flags, charge documents trail and director networks for Grindlays Pharma - groundwork for KYC, onboarding and disputes.
13
Frequently Asked Questions
Is Grindlays Pharma an active company?
Grindlays Pharma has MCA status “Active” with a compliance score of 100/100 (Low Risk).
Is Grindlays Pharma financially healthy?
Grindlays Pharma has a Financial Health Score of 90/100 (Low Risk) based on its filed financial statements.
Should I do business with Grindlays Pharma?
Its overall Trust Score is 95/100 (Low Risk). Vendor verdict: Favourable indicators. Review the risk flags in the Risk Intelligence Center before deciding.
Who controls Grindlays Pharma?
Promoters hold a dominant controlling stake - exact percentages are in the full report. 4 active director(s) are on record.
Does Grindlays Pharma have loans or charges against its assets?
1 open charge(s) are registered against its assets, and 7 earlier charge(s) stand satisfied.
Is Grindlays Pharma up to date with its ROC filings?
Annual filings current (balance sheet Mar 2025). Overall compliance score: 100/100 (Low Risk).
Is it risky to lend to Grindlays Pharma?
Its Credit Risk Score is 60/100 (Moderate). Banker verdict: Favourable lending indicators.
Disclaimer: This report is generated automatically from MCA filings and public records as available
in our system at the time of the last update. Scores, bands and verdicts are rule-based derived indicators of the
underlying data - they are opinions generated by an algorithm, not statements of fact about the company, and are
not credit ratings (within the meaning of SEBI regulations), audits, or investment, legal or financial advice.
Verify from official sources and consult a qualified professional before any business, lending or investment decision.
If you represent this company and believe any information is inaccurate or outdated,
report it here and we will review promptly.
